Comparing two treatments for patients with complex coronary lesions undergoing PCI
Official title: Aspirin and a Potent P2Y12 Inhibitor Versus Aspirin and Clopidogrel Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention for Complex Lesion Treatment (SMART-ATTEMPT)
Run by Samsung Medical Center · NCT04014803 · Data updated 2026-11-12
This study is testing whether using aspirin with prasugrel or aspirin with clopidogrel is better for people with complex heart issues who are having a procedure to open blocked arteries.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years to 75 Years |
| Sex | All |
| Enrollment | 3500 (estimated) |
| Sponsor | Samsung Medical Center Academic / other |
| Locations | 2 sites (Seoul and 1 other locations) |
| Status | Recruiting |
| Started | January 13, 2020 |
| Main results expected | June 30, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | February 9, 2026 |
| Trial ID | NCT04014803 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 19 and older undergoing elective PCI for complex coronary lesions.
✕Probably not a fit
Patients with non-complex coronary lesions or those not undergoing PCI may not receive benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the efficacy and safety of dual antiplatelet therapy using aspirin combined with prasugrel versus aspirin combined with clopidogrel in patients undergoing elective percutaneous coronary intervention (PCI) for complex coronary lesions. It is a prospective, open-label, two-arm, randomized multicenter trial aimed at reducing ischemic events in this high-risk population. The study will assess the optimal duration of treatment and the potential benefits of using a more potent P2Y12 inhibitor in conjunction with aspirin. Participants will be monitored for ischemic events and safety outcomes over the course of the treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies that significantly reduce the risk of ischemic events in patients with complex coronary lesions.
How similar studies have gone: Other studies have shown promising results with similar dual antiplatelet therapy approaches, indicating potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ① Subject must be at least 19 years of age * ② Subject who can verbally confirm understandings of risks, benefits and treatment alternatives and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure * ③ Patients undergoing elective PCI as follows: 1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5 mm size 2. Chronic total occlusion (≥3 months) as target lesion 3. PCI for unprotected left main disease (left main ostium, body, or distal bifurcation including non-true bifurcation lesions) 4. Long coronary lesions (expected stent length ≥38 mm) 5. Multi-vessel PCI (≥2 vessels treated at one PCI session) 6. Multiple stent needed (≥3 stents per patient) 7. In-stent restenosis lesion as target lesion 8. Severely calcified lesion (encircling calcium in angiography) 9. Ostial lesions of left anterior descending artery, left circumflex artery, or right coronary artery Exclusion Criteria: * ① Hemodynamic instability or cardiogenic shock * ② Subjects with serious bleeding (Intracerebral hemorrhage, gastrointestinal bleeding, hematuria, hemoptysis, and etc.) * ③ Previous history of intracerebral hemorrhage, transient ischemic attack, or stroke * ④ Known hypersensitivity or contraindications to study medications (aspirin, clopidogrel, and prasugrel) * ⑤ Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study * ⑥ Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment) * ⑦ Patients presenting with biomarker positive acute coronary syndrome * ⑧ Patients chronically taking prasugrel or ticagrelor (≥1 week) * ⑨ Subjects ≥75 years of age or \<60 kg of body weight * ⑩ Patients taking warfarin or novel oral anticoagulants (dabigatran, rivaroxaban, edoxaban, or apixaban) * Eligible patients will be randomly assigned to treatment arms, stratified by participating centers, presence of diabetes mellitus, and stent types.
Where it's running
-
Samsung Medical Center
Seoul, South Korea Recruiting -
Samsung Medical Center
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Joo-Yong Hahn, MD, PhD
- Email: ichjy1@gmail.com
- Phone: 82-2-3410-1246
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.